hCG 10000iu Injection (Human Chorionic Gonadotropin)

Product Overview

hCG 10000iu Injection, manufactured by Sanzyme Biologics (P) Ltd, is a lyophilized preparation of human chorionic gonadotropin supplied in a 1 ml sealed vial. The product is delivered as a sterile powder that must be reconstituted with the accompanying diluent before administration, either sub‑cutaneously or intramuscularly. Pack configurations include 5, 10, or 20 vials per pack, allowing clinics to select the quantity that best fits treatment volume. The active ingredient is recombinant HCG, a glycoprotein hormone that mimics the natural luteinizing hormone (LH) activity essential for gonadal stimulation. Storage requires refrigeration at 2 °C to 8 °C, and the vial should be protected from light until reconstitution. This medication is intended for use under the supervision of a qualified healthcare professional and is indicated for the treatment of female infertility associated with ovulatory dysfunction and for male hypogonadism resulting from insufficient endogenous gonadotropin secretion.

What is hCG 10000iu Injection

Human chorionic gonadotropin (hCG) is a hormone produced by the placenta during early pregnancy and consists of two subunits, α and β, that together form the biologically active molecule. In pharmaceutical form, recombinant hCG is engineered to replicate the native hormone’s structure and function, ensuring consistent biological activity. The 10000 International Units (IU) strength reflects the biologically active potency measured by in‑vitro immunoassays and cell‑based assays. This dosage is commonly employed in assisted reproductive technologies (ART) to trigger the final maturation of ovarian follicles and to support luteal phase maintenance. In endocrinology, the same preparation can stimulate Leydig cell activity in men with primary or secondary hypogonadism, thereby enhancing testosterone synthesis. The injection is administered after reconstitution with the supplied diluent, and the resulting solution should be inspected visually for clarity, absence of particulate matter, and correct color before use.

Uses and Benefits

The primary clinical benefit of hCG 10000iu Injection lies in its ability to induce ovulation in women with polycystic ovary syndrome (PCOS) or other ovulatory disorders when used in conjunction with follicular monitoring via transvaginal ultrasound. By mimicking the luteinizing hormone surge, the medication promotes the release of the mature oocyte, increasing the likelihood of conception and supporting natural or assisted pregnancy pathways. In male patients, the hormone stimulates Leydig cells to produce testosterone, which can improve libido, energy levels, and, when combined with adequate spermatogenic support, may enhance sperm parameters in cases of secondary hypogonadism. Additional therapeutic contexts include the treatment of cryptorchidism in pediatric endocrinology and the use of hCG as part of post‑cycle therapy to restore endogenous hormone production after anabolic steroid withdrawal. The standardized potency of each 10000 IU vial ensures consistent dosing across treatment cycles, supporting predictable therapeutic outcomes and simplifying protocol design for clinicians.

How It Works

Upon administration, hCG binds to LH receptors on ovarian granulosa and theca cells, triggering intracellular signaling pathways that culminate in the synthesis of cyclic adenosine monophosphate (cAMP). This cascade leads to the final maturation of the pre‑ovulatory follicle and the subsequent release of the oocyte from the ovarian follicle. In males, hCG engages Leydig cell LH receptors, activating steroidogenic enzymes such as cholesterol side‑chain cleavage enzyme and 17α‑hydroxylase/17,20‑lyase, which increase production of testosterone and, consequently, dihydrotestosterone (DHT). The hormone’s half‑life of approximately 30 hours allows for a single dose to maintain sufficient receptor activation over several days, which is why it is often given as a one‑time injection rather than multiple daily doses. The pharmacodynamic effect is dose‑dependent, with higher IU amounts producing a more pronounced LH‑like response, and the magnitude of the response can be modulated by patient‑specific factors such as body mass index, baseline hormone levels, and concurrent medications.

Dosage Guidelines

Dosage of hCG 10000iu Injection is individualized based on the underlying condition, patient age, baseline hormone levels, and response to prior therapy. In female infertility protocols, a typical regimen involves a single 10,000 IU dose administered after ultrasound confirmation of follicular maturity, usually when the leading follicle reaches a mean diameter of 18–20 mm, followed by timed intercourse, intrauterine insemination, or oocyte retrieval for in‑vitro fertilization. For male hypogonadism, clinicians may prescribe a course of 1,000–2,000 IU administered two to three times per week for several weeks, with dose adjustments guided by serum testosterone measurements and symptom monitoring. Ongoing monitoring typically includes serial hormone assays and, when indicated, imaging to assess follicular development or testicular volume changes. Patients should receive clear instructions on reconstitution, handling, and injection technique from a qualified healthcare provider, and any missed dose should be discussed with the prescribing clinician rather than doubled up.

Side Effects

Like all biologic agents, hCG 10000iu Injection may be associated with adverse effects, although most are mild and transient. Common side effects include injection site reactions such as redness, swelling, or bruising, as well as headache, fatigue, and mild abdominal discomfort. Less frequently, patients may experience nausea, vomiting, breast tenderness, or temporary water retention, which typically resolve without medical intervention. Rare but serious complications can include ovarian hyperstimulation syndrome (OHSS) in women, which manifests as abdominal distension, shortness of breath, rapid weight gain, and decreased urine output, and allergic reactions ranging from mild skin rash to anaphylaxis, which may present as difficulty breathing, swelling of the face or throat, and hypotension. Patients should seek immediate medical attention if they develop severe pelvic pain, sudden weight gain exceeding 5 kg within a few days, or signs of an allergic response such as urticaria or respiratory distress.

Warnings and Precautions

hCG 10000iu Injection is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients, as well as in patients with active or suspected pregnancy, ovarian cysts unrelated to polycystic ovary syndrome, or certain types of hormone‑sensitive tumors. Caution is advised in patients with thyroid disorders, adrenal insufficiency, or seizure disorders, as hormonal fluctuations may exacerbate underlying conditions. Prior to initiation, a thorough medical history and laboratory evaluation—including serum pregnancy tests, baseline hormone panels, and lipid profiles—are recommended. Women of child‑bearing potential must use effective contraception during treatment cycles to avoid unintended pregnancy, and clinicians should discuss the risks and benefits of treatment with each patient. The medication should be stored in a refrigerator and protected from freezing; once reconstituted, the solution should be used within the timeframe specified by the manufacturer, typically within 30 minutes, and any unused portion should be discarded to prevent contamination.

Frequently Asked Questions

Q1: What is the recommended storage condition for hCG 10000iu Injection?
A1: The vials should be refrigerated at 2 °C to 8 °C and kept away from light. Do not freeze. Once reconstituted, the solution can be kept at room temperature for up to 30 minutes before administration.

Q2: Can hCG be used to improve sperm count in men?
A2: Yes, in men with secondary hypogonadism, hCG can stimulate Leydig cells to produce testosterone, which may indirectly improve spermatogenesis when combined with appropriate clinical monitoring.

Q3: How soon after injection can ovulation occur?
A3: Ovulation typically occurs 36 to 48 hours after a single 10,000 IU dose when used in conjunction with follicular monitoring, though individual response may vary.

Q4: Is hCG safe during pregnancy?
A4: hCG is contraindicated in pregnant women because it may interfere with the natural hormonal environment and could affect embryo development.

Q5: Where can I find more authoritative information about hCG therapy?
A5: Trusted resources include the National Institutes of Health, the U.S. Food and Drug Administration, and MedlinePlus for patient‑focused explanations.

Related Products

• Letrozole 2.5 mg (Generic)
• Estradiol 2 mg (Generic)
• Progesterone 50 mg Injection (Generic)
• Ovidac (HCG (HUMAN CHORIONIC GONADOTROPIN))
• hMG 1200iu Injection (Menotrophin)
• hCG 5000iu Injection (Human Chorionic Gonadotropin)
• hMG 150iu Injection (Menotrophin)
• hMG 75iu Injection (Menotrophin)
• Progesterone 400 mg (Progesterone)
• Ovidac 10000 iu (HCG (Human Chorionic Gonadotropin))
• Fertigyn 10000 iu (HCG 10000iu)
• Ovidac 5000iu (HCG (Human Chorionic Gonadotropin))